Back to search

Article

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer

2025-11-13

Abstract excerpt

Prostate cancer (PC) remains the second leading cause of cancer-related mortality in men. The emergence of treatment-emergent neuroendocrine prostate cancer (NEPC) arising from androgen receptor (AR) pathway inhibition poses a significant clinical challenge. Here, we report that NUAK family kinase 2 (NUAK2) is an actionable therapeutic target in NEPC. NUAK2 expression is markedly elevated in NEPC patient specimens...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1a61b745-8227-5a81-9d85-920dc48c5d63
DOI
10.1101/2025.11.12.687734
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancerDOI 10.1101/2025.11.12.687734
NUAK family kinase 2 is a novel therapeutic target for prostate cancerSemantic proximity
Spliceosomic dysregulation unveils <i>NOVA1</i> as an actionable therapeutic target in pancreatic neuroendocrine tumorsSemantic proximity
Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus responseSemantic proximity
NEK2 is a potential pan-cancer biomarker and immunotherapy targetSemantic proximity
A Pan-Cancer Analysis Reveals OAS2 as a Biomarker for Cancer Prognosis and ImmunotherapySemantic proximity
Dysregulation of CELF4 splicing factor in pancreatic neuroendocrine tumors enhances aggressiveness and alters mTOR pathway and everolimus responseSemantic proximity
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity
Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugsSemantic proximity
Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13Semantic proximity
Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumorsSemantic proximity
A Comprehensive Analysis Revealing NEK2 as an oncogene in the Tumor MicroenvironmentSemantic proximity
Mapping the NFYA 3′UTR landscape identifies alternative polyadenylation as a targetable vulnerability in prostate cancerSemantic proximity
Select a neighboring publication to make it the new centre.